Ability Pharma, a CataloniaBio & HealthTech member with shareholders Inveready, Everis and Sodena, will receive €5 million from the Horizon EIC Accelerator programme (successor of the SME Instrument).

The EIC Accelerator provides grant-only support as well as support in the form of blended finance. In fact, Ability Pharma has been awarded 2.5 million as a grant and 2.5 million as a equity managed by the European Investment Bank (EBI).

This biopharmaceutical company based at the UAB Research Park will use these funds to begin a Phase-IIb clinical trial with the ABTL0812 anti-tumour compound on pancreatic cancer. ABTL0812 is currently being tested in other clinical trials on endometrial and lung cancer.

You may also be interested in:

• Ability Pharma closes €2.3-million round
• Ability Pharma closes €1.2-million round with Capital Cell